ClinicalTrials.gg

Program

vunakizumab

Also written as “SHR-1314”, “SHR-1314 injection” and “SHR-1314 Injection”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Non-Radiographic Axial Spondyloarthritis · Graves Ophthalmopathy · Spondylitis, Ankylosing, led by Jiangsu HengRui Medicine.

Furthest: phase 4, since Jan 7, 202517 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine174 open or runningphase 4since Jan 7, 2025Sep 20, 2016Mar 2027phase 4 · NCT06779097

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Sep 20, 2016.

  1. Jan 22, 2018Phase 2 study in Moderate-to-severe Chronic Plaque PsoriasisNCT03463187 · 211 enrolled · United States, Australia, China
  2. Sep 6, 20182 phase 1 studiesNCT03710681, NCT03704428
  3. Sep 27, 2019Phase 2 study in Plaque PsoriasisNCT04121143 · 120 enrolled · China
  4. Mar 24, 2020Phase 1 study in PharmacokineticNCT04326881 · 30 enrolled
  5. Aug 23, 2020Phase 1 study in BioequivalenceNCT04527484 · 130 enrolled
  6. Apr 7, 20212 phase 3 studiesNCT04840485, NCT04839016
  7. Jun 7, 2021Phase 2 study in Lupus NephritisNCT04924296 · 60 enrolled
  8. Sep 15, 2021Phase 2 study in Arthritis, PsoriaticNCT05055934 · 112 enrolled · China
  9. May 23, 2022Phase 2 study in Active Moderate to Severe Graves' OrbitopathyNCT05394857 · 7 enrolled · China
  10. Dec 4, 2023Phase 1 study in Moderate-to-Severe Plaque PsoriasisNCT06182384 · 46 enrolled · China
  11. Oct 10, 2024Phase 3 study in Arthritis, PsoriaticNCT06640257 · 208 enrolled · China
  12. Jan 7, 2025Phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097 · 1,564 planned · China
  13. Feb 11, 2025Phase 3 study in Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque PsoriasisNCT06833307 · 90 planned · China
  14. Mar 2, 2025Phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750 · 380 planned · China

Ahead

  1. Mar 2027Primary completion: phase 4 study in Moderate to Severe Plaque PsoriasisNCT06779097
  2. Feb 2028Primary completion: phase 3 study in Active Non-radiographic Axial SpondyloarthritisNCT06860750

TargetBeta

IL17A →read by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
ixekizumabruleEli Lillyphase 438
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06860750Active Non-radiographic Axial Spondyloarthritis · China3RecruitingFeb 2028380
NCT06833307Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis · China3Not yet recruitingJul 202690
NCT06779097Moderate to Severe Plaque Psoriasis · China4Not yet recruitingMar 20271,564
NCT06640257Arthritis, Psoriatic · China3Active, not recruitingJun 5, 2026208
NCT06182384Moderate-to-Severe Plaque Psoriasis · China1CompletedMay 13, 202446
NCT05394857Active Moderate to Severe Graves' Orbitopathy · China2TerminatedAug 22, 20237
NCT05055934Arthritis, Psoriatic · China2CompletedJun 5, 2024112
NCT04924296Lupus Nephritis2UNKNOWNDec 25, 202160
NCT04839016Moderate-to-Severe Plaque Psoriasis3UNKNOWNAug 30, 2023660
NCT04840485Spondylitis, Ankylosing · China3CompletedNov 3, 2023548
NCT04527484Bioequivalence1UNKNOWNJan 10, 2021130
NCT04326881Pharmacokinetic1UNKNOWNJul 7, 202030
NCT04121143Plaque Psoriasis · China2SuspendedJun 30, 2020120
NCT03704428Axial Spondyloarthritis · China1CompletedJan 14, 202045
NCT03710681Moderate-to-severe Plaque Psoriasis · China1UNKNOWNApr 21, 201916
NCT03463187Moderate-to-severe Chronic Plaque Psoriasis · United States, Australia, China2CompletedAug 31, 2020211
NCT02934412Psoriasis · Australia1CompletedJun 30, 201740

How it is read

Names in the registry

  • “SHR-1314”, 14 entries
  • “SHR-1314 injection”, 2 entries
  • “SHR-1314 Injection”, 1 entry
  • “Vunakizumab (IL-17A inhibitor)”, 1 entry
  • “IL-17A Antagonist”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.